161 related articles for article (PubMed ID: 31502843)
1. Structural Characterization of Agonist Binding to an A
Stamatis D; Lagarias P; Barkan K; Vrontaki E; Ladds G; Kolocouris A
J Med Chem; 2019 Oct; 62(19):8831-8846. PubMed ID: 31502843
[TBL] [Abstract][Full Text] [Related]
2. Insights to the Binding of a Selective Adenosine A
Lagarias P; Barkan K; Tzortzini E; Stampelou M; Vrontaki E; Ladds G; Kolocouris A
J Chem Inf Model; 2019 Dec; 59(12):5183-5197. PubMed ID: 31725294
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterisation of novel adenosine A
Barkan K; Lagarias P; Stampelou M; Stamatis D; Hoare S; Safitri D; Klotz KN; Vrontaki E; Kolocouris A; Ladds G
Sci Rep; 2020 Nov; 10(1):20781. PubMed ID: 33247159
[TBL] [Abstract][Full Text] [Related]
4. Effects of synthetic A3 adenosine receptor agonists on cell proliferation and viability are receptor independent at micromolar concentrations.
Mlejnek P; Dolezel P; Frydrych I
J Physiol Biochem; 2013 Sep; 69(3):405-17. PubMed ID: 23184730
[TBL] [Abstract][Full Text] [Related]
5. Structure-Activity Analysis of Biased Agonism at the Human Adenosine A3 Receptor.
Baltos JA; Paoletta S; Nguyen AT; Gregory KJ; Tosh DK; Christopoulos A; Jacobson KA; May LT
Mol Pharmacol; 2016 Jul; 90(1):12-22. PubMed ID: 27136943
[TBL] [Abstract][Full Text] [Related]
6. Adenosine A3 receptor activation is neuroprotective against retinal neurodegeneration.
Galvao J; Elvas F; Martins T; Cordeiro MF; Ambrósio AF; Santiago AR
Exp Eye Res; 2015 Nov; 140():65-74. PubMed ID: 26297614
[TBL] [Abstract][Full Text] [Related]
7. Different efficacy of adenosine and NECA derivatives at the human A3 adenosine receptor: insight into the receptor activation switch.
Dal Ben D; Buccioni M; Lambertucci C; Kachler S; Falgner N; Marucci G; Thomas A; Cristalli G; Volpini R; Klotz KN
Biochem Pharmacol; 2014 Jan; 87(2):321-31. PubMed ID: 24161786
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and evaluation of N⁶-substituted apioadenosines as potential adenosine A₃ receptor modulators.
Toti KS; Moss SM; Paoletta S; Gao ZG; Jacobson KA; Van Calenbergh S
Bioorg Med Chem; 2014 Aug; 22(15):4257-68. PubMed ID: 24931275
[TBL] [Abstract][Full Text] [Related]
9. Activation of Adenosine A
Ferreira-Silva J; Aires ID; Boia R; Ambrósio AF; Santiago AR
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33007835
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.
Baraldi PG; Cacciari B; Pineda de Las Infantas MJ; Romagnoli R; Spalluto G; Volpini R; Costanzi S; Vittori S; Cristalli G; Melman N; Park KS; Ji XD; Jacobson KA
J Med Chem; 1998 Aug; 41(17):3174-85. PubMed ID: 9703463
[TBL] [Abstract][Full Text] [Related]
11. Functional expression of adenosine A2A and A3 receptors in the mouse dendritic cell line XS-106.
Dickenson JM; Reeder S; Rees B; Alexander S; Kendall D
Eur J Pharmacol; 2003 Aug; 474(1):43-51. PubMed ID: 12909194
[TBL] [Abstract][Full Text] [Related]
12. Adenosine A3 receptor activation attenuates lung ischemia-reperfusion injury.
Mulloy DP; Sharma AK; Fernandez LG; Zhao Y; Lau CL; Kron IL; Laubach VE
Ann Thorac Surg; 2013 May; 95(5):1762-7. PubMed ID: 23541429
[TBL] [Abstract][Full Text] [Related]
13. Activation of adenosine A3 receptors reduces ischemic brain injury in rodents.
Chen GJ; Harvey BK; Shen H; Chou J; Victor A; Wang Y
J Neurosci Res; 2006 Dec; 84(8):1848-55. PubMed ID: 17016854
[TBL] [Abstract][Full Text] [Related]
14. The effects of the adenosine A3 receptor agonist IB-MECA on sodium taurocholate-induced experimental acute pancreatitis.
Prozorow-Krol B; Korolczuk A; Czechowska G; Slomka M; Madro A; Celinski K
Arch Pharm Res; 2013 Sep; 36(9):1126-32. PubMed ID: 23625750
[TBL] [Abstract][Full Text] [Related]
15. Probing structure-activity relationship in β-arrestin2 recruitment of diversely substituted adenosine derivatives.
Storme J; Tosh DK; Gao ZG; Jacobson KA; Stove CP
Biochem Pharmacol; 2018 Dec; 158():103-113. PubMed ID: 30292756
[TBL] [Abstract][Full Text] [Related]
16. The synthesis of a series of adenosine A3 receptor agonists.
Broadley KJ; Burnell E; Davies RH; Lee AT; Snee S; Thomas EJ
Org Biomol Chem; 2016 Apr; 14(15):3765-81. PubMed ID: 27001924
[TBL] [Abstract][Full Text] [Related]
17. Docking studies of agonists and antagonists suggest an activation pathway of the A3 adenosine receptor.
Kim SK; Gao ZG; Jeong LS; Jacobson KA
J Mol Graph Model; 2006 Dec; 25(4):562-77. PubMed ID: 16793299
[TBL] [Abstract][Full Text] [Related]
18. Activation of adenosine A3 receptor reduces early brain injury by alleviating neuroinflammation after subarachnoid hemorrhage in elderly rats.
Li P; Li X; Deng P; Wang D; Bai X; Li Y; Luo C; Belguise K; Wang X; Wei X; Xia Z; Yi B
Aging (Albany NY); 2020 Nov; 13(1):694-713. PubMed ID: 33253120
[TBL] [Abstract][Full Text] [Related]
19. Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000.
Gao ZG; Ye K; Göblyös A; Ijzerman AP; Jacobson KA
BMC Pharmacol; 2008 Dec; 8():20. PubMed ID: 19077268
[TBL] [Abstract][Full Text] [Related]
20. A3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve.
González-Fernández E; Sánchez-Gómez MV; Pérez-Samartín A; Arellano RO; Matute C
Glia; 2014 Feb; 62(2):199-216. PubMed ID: 24311446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
